JUBLIA

Welcome to the Brand page for “JUBLIA”, which is offered here for In the statement, line 1-4, should be deleted, and, valeant international bermuda, a bermuda unlimited liability company, clarendon house 2 church street hamilton, bermuda hm11 should be inserted.;pharmaceutical preparations, pharmaceutical preparations and substances for the treatment of skin disorders, diseases, conditions and ailments; pharmaceutical preparations and products for use in dermatology; antifungal preparations [ ; pharmaceutical preparations and substances for the treatment of eye disorders, diseases, conditions and ailments; pharmaceutical preparations and products for ophthalmological use; pharmaceutical preparations and substances for the treatment of disorders, diseases, conditions and ailments of the central nervous system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of anxiety, depression, depressive disorders and mental illness; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the cardiovascular system ];.

Its status is currently believed to be active. Its class is unavailable. “JUBLIA” is believed to be currently owned by “BAUSCH HEALTH IRELAND LIMITED”.


Owner:
BAUSCH HEALTH IRELAND LIMITED
Owner Details
Description:
In the statement, line 1-4, should be deleted, and, VALEANT INTERNATIONAL BERMUDA, a Bermuda unlimited liability company, CLARENDON HOUSE 2 CHURCH STREET HAMILTON, BERMUDA HM11 should be inserted.;Pharmaceutical preparations, pharmaceutical preparations and substances for the treatment of skin disorders, diseases, conditions and ailments; pharmaceutical preparations and products for use in dermatology; antifungal preparations [ ; pharmaceutical preparations and substances for the treatment of eye disorders, diseases, conditions and ailments; pharmaceutical preparations and products for ophthalmological use; pharmaceutical preparations and substances for the treatment of disorders, diseases, conditions and ailments of the central nervous system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of anxiety, depression, depressive disorders and mental illness; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the cardiovascular system ];
Categories: STATEMENT